BIOGEN INC. (BIIB) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions and 3 funds trimming or exiting versus the previous quarter. 2 members of Congress reported 4 purchases vs 3 sales. Latest close $251.41 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Hillman Capital Management · Patient Capital Management · Perceptive Advisors — 5 tracked funds hold BIIB. See all holders.
2 members of Congress reported buying (4 purchases vs 3 sales). Latest buy: Jun 5, 2026. Politician trading
BOSTON SCIENTIFIC CORP (BSX) · AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · Immunovant, Inc. (IMVT) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Hillman Capital Management | 3.75% | 23,993 | TRIMMED (-18.8%) Q3 filed Nov 16 |
| Patient Capital Management | 2.01% | 283,697 | TRIMMED (-25.3%) Q3 filed Nov 12 |
| Perceptive Advisors | 0.90% | 276,173 | NEW Q3 filed Nov 16 |
| Causeway Capital Management | 0.65% | 278,283 | TRIMMED (-0.9%) Q3 filed Nov 13 |
| OrbiMed Advisors | 0.25% | 61,600 | HELD Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +19.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 1,045 of 8,857 filers |
| Long-only filers among them | 1,035 |
| Change vs 2026 Q1 | +57 net · 942 entered · 885 exited |
| Shares reported, all filers | 140,647,629 |
| Reported value, all filers | $30.6B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) (SIC 2836) |
| Revenue · FY2025 | $9.9B |
| Net income · FY2025 | $1.3B |
| Total assets · FY2025 | $29.4B |
| Shares outstanding | 147,820,223 |
| Market cap (at latest close) | $37.2B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 26, 2026.
| Shares short · Oct 15, 2026 | 5,500,386 |
| Share of shares outstanding | 3.72% |
| Days to cover | 4.39 |
Shares short at recent settlements — Jul 31, 2026: 5.5M · Aug 14, 2026: 5.2M · Aug 31, 2026: 5.7M · Sep 15, 2026: 5.8M · Sep 30, 2026: 6.0M · Oct 15, 2026: 5.5M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 26, 2026.
| Shares failed to deliver · Oct 14, 2026 | 2,091 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | <0.1% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 2K.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 26, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | Minor Lloyd | Director | 593 | $119.2K | Aug 4, 2026 | SEC filing |
| Aug 3, 2026 | Minor Lloyd | Director | 593 | $120.6K | Aug 3, 2026 | SEC filing |
| Feb 9, 2026 | Singhal Priya | Officer | 2,660 | $531.5K | Feb 9, 2026 | SEC filing |
| Feb 2, 2026 | Singhal Priya | Officer | 748 | $134.1K | Feb 2, 2026 | SEC filing |
| Sep 2, 2025 | Singhal Priya | Officer | 517 | $69.0K | Sep 2, 2025 | SEC filing |
| Jul 8, 2025 | Izzar Rachid | Officer | 2,223 | $300.1K | Jul 8, 2025 | SEC filing |
| May 19, 2025 | Singhal Priya | Officer | 3,806 | $480.5K | May 19, 2025 | SEC filing |
| Mar 7, 2025 | STEPHEN A SHERWIN | Director | 8,760 | $1.3M | Mar 7, 2025 | SEC filing |
| Dec 9, 2024 | Singhal Priya | Officer | 110 | $17.3K | Dec 9, 2024 | SEC filing |
| Sep 3, 2024 | Singhal Priya | Officer | 431 | $88.0K | Sep 3, 2024 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | FMR LLC | SC 13G/A | 18,294,523.51 | 12.4% | Jun 30, 2026 | SEC filing |
| Jun 5, 2026 | FMR LLC | SC 13G/A | 16,652,974.82 | 11.3% | May 29, 2026 | SEC filing |
| May 6, 2026 | FMR LLC | SC 13G/A | 12,807,541.5 | 8.7% | Mar 31, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Capital Management | SC 13G | 10,989,562 | 7.5% | Mar 31, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 5, 2026 | FMR LLC | SC 13G | 9,413,062.03 | 6.4% | Dec 31, 2025 | SEC filing |
| Nov 13, 2025 | PRIMECAP MANAGEMENT CO/CA/ | SC 13G/A | 14,954,697 | 10.2% | Sep 30, 2025 | SEC filing |
| Nov 10, 2025 | STATE STREET CORPORATION | SC 13G | 7,321,168 | 5.0% | Sep 30, 2025 | SEC filing |
| Apr 17, 2025 | BlackRock, Inc. | SC 13G/A | 12,506,681 | 8.5% | Mar 31, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
2 members of Congress reported buying (4 purchases vs 3 sales). Bought by Democrats and Republicans. Latest buy: Jun 5, 2026.
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Salazar, Maria Elvira | House | R | 3 | 2 | Sep 24, 2026 | $1,001 - $15,000 |
| Hern, Kevin | House | R | 0 | 1 | Aug 18, 2026 | $1,001 - $15,000 |
| Cisneros, Gilbert | House | D | 1 | 0 | Jun 5, 2026 | $1,001 - $15,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 222 Lobbying Disclosure Act filings named this company as client, 2000–2026; most common issues: Health Issues (156), Medicare/Medicaid (153), Taxation/Internal Revenue Code (68).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Politicians
· Bought by Members — Last 6 months: bought by a member of the U.S. Congress
· Bought by Both Parties — Last 6 months: bought by both Democratic and Republican members
Financial Screens
· Graham — Sound finances and a long run of profits
· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%
· Gross Profitability (Novy-Marx) — High gross profit relative to total assets
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Graham — Current ratio: 2.68 · Straight profitable years: 19 · Debt ratio: 0.61 · Latest net income: $1.3B
· Cash Flow (FCF) — Latest FCF: $2.1B · FCF yield: 5.6% · Positive FCF years: 3
· Gross Profitability (Novy-Marx) — Gross profit / assets: 47.3% · Gross margin: 86.6%
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.60 · Operating cash flow: $2.2B · Net income: $1.3B
· Bought by Members — Members buying: 2 · Buy txns: 4 · Sell txns: 3 · Latest buy: Jun 5, 2026
· Bought by Both Parties — Members buying: 2 · Buy txns: 4 · Sell txns: 3 · Latest buy: Jun 5, 2026
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2026 Q2, ranked #11 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 5 | 60.0% | +11.4% | +3.5% | +7.9% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold BIIB — ranked by lift, the co-holding pattern described in Methodology: BOSTON SCIENTIFIC CORP (BSX) · AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · Immunovant, Inc. (IMVT) · REPLIGEN CORP (RGEN) · BIO-TECHNE Corp (TECH) · Vaxcyte, Inc. (PCVX).
7 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
Filings audit: every filing lens on BIOGEN INC. (BIIB), scored — GetCoattail Research.
| Filed | Items | Source |
|---|---|---|
| Oct 28, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Jul 29, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Jul 1, 2026 | 2.02 Results of Operations and Financial Condition | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
BOSTON SCIENTIFIC CORP (BSX) · Filings audit: every filing lens on BIOGEN INC. (BIIB), scored · Practice timing on BIIB
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.